Semaglutide

Sep 21, 2026

Summary Semaglutide patent expiry is staggered, not simultaneous: early wave in 2026 (India, China, Brazil, Canada, South Africa), mid wave ~2031 (UK, EU4, Japan), late wave 2032–33 (US). India and China are the biggest near-term battlegrounds, covering ~40% of the world population and a third of global obes...

Sep 08, 2026

Novo Nordisk’s STEP Young Phase 3 Study Shows Semaglutide Reduced Obesity Classification in 40.4% of Children Novo Nordisk announced the initial results from the STEP Young Phase 3 trial, which evaluated once-weekly semaglutide in combination with lifestyle modifications, including a reduced-calorie diet and inc...

Feb 12, 2025

Alzheimer’s disease is a devastating neurodegenerative disorder that affects millions worldwide, progressively impairing memory, cognitive function, and independence. Despite extensive research, current Alzheimer’s disease drugs provide only limited relief, and there remains no cure. With the number of cases projec...

Sep 27, 2024

On 11 September 2024, the latest results from the FLOW trial were presented at the European Association for the Study of Diabetes (EASD) conference in Madrid, Spain. The FLOW trial, initiated in 2019, was a global, multinational, randomized controlled trial conducted across 28 countries, 387 sites, and 3,533 partic...

Aug 31, 2018

Use of Placebo is Necessary Only in Certain Types of Oncology Trials: USFDA In a new draft guidance released, the USFDA is questioning whether or not the use of a placebo in a double-blind, randomized clinical trial is always necessary. The FDA said sometimes the use of a placebo can present practical or ethical co...